Febit Goes Belly-up Shortly After Product Launch; New Geniom One Owner Unknown | GenomeWeb

Febit, the German start-up whose entry into the microarray field was eagerly anticipated, has gone bankrupt and shut down its operations just months after commercializing its first product.

The Mannheim-based firm had pocketed slightly more than half of a €30 million ($30.3 million) round of private financing in late 2002, the company’s third, which was expected to help Febit launch its first product and increase staff from 75 to 120 employees.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.